Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.

Giusy TiseoChiara BarbieriValentina GalfoSara OcchineriTommaso MatucciFrancesco AlmerigognaJona KaloPietro SpongaMario CesarettiGabriele MarchettiArianna FornitiClaudio CaroselliSimone FerrantiManuela PogliaghiMarina PolidoriSilvia FabianiStefano VerdenelliEnrico TagliaferriNiccolò RiccardiLorenzo Roberto SuardiClaudia CarmignaniSerena BatiniLuca PuccettiRiccardo IapoceFrancesco MenichettiMarco Falcone

Published in: Infectious diseases and therapy (2022)

Death or hospitalization did not differ among high-risk COVID-19 outpatients treated with currently available antivirals. Safety and time to a negative test differed among the three drugs.

Keyphrases

coronavirus disease
sars cov
primary care
respiratory syndrome coronavirus
newly diagnosed